Stage III Thoracic Cancer Debates
The course consists of two debates. The first debate consists of two thoracic oncologists with one arguing for the use of surgery and one against the use of surgery for patients with stage III NSCLC. The second debate puts two radiation oncologists with one arguing for proton beam therapy and the other for standard IMRT for treatment of patients with locally advanced NSCLC. Each discussant will have about 10 minutes to present their argument followed by 10 minutes for rebuttal and questions from the moderator and audience.
An additional presentation on the combining Immunotherapy and Radiation Therapy provides attendees with educational tools to narrow knowledge gaps with regards the use of biomarkers to optimize patient selection for cancer immunotherapy.
This activity is available from January 31, 2022, through 11:59 p.m. Eastern time on January 30, 2025.
This activity was originally recorded at ASTRO’s Multidisciplinary Thoracic Cancers Symposium, December 2-4th.
The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, surgeons, physicists, nurses, radiation dosimetrists, radiation therapists, diagnostic radiologists, pathologists, medical oncologists and other specialists.
Upon completion of this activity, participants should be able to:
- Discuss the benefits and risks of trimodality therapy vs. chemoradiotherapy for patients with stage III NSCLC.
- Discuss the benefits and risks of proton therapy vs. IMRT for patients with stage III NSCLC.
- Educate patients and assist in shared decision-making regarding curative treatment options for stage III NSCLC.
- Appraise the biological mechanisms underlying the application of immune checkpoint inhibitors in the context of radiotherapy in the treatment of Stage III NSCLC.
Moderator: Gregory P. Kalemkerian, MD, University of Michigan, Ann Arbor, Michigan and receives compensation from BVD, Infinity, Boston Biomed, Skyline, Synlogic, Merck, Takeda, Abbvie, Blueprint, Daiichi-Sankyo, Cullinan, Takeda, and Unum.
- Keith Naunheim, MD, St. Louis University, St. Louis, Missouri and has nothing to disclose.
- Elliot Wakeam, MD, University of Michigan, Ann Arbor, Michigan and has nothing to disclose.
- Jeffrey Bradley, MD, FASTRO, Emory University School of Medicine, Atlanta and receives compensation from Genentech, Mevion Medical Systems and Varian Medical Systems, Inc.
- Sue Yom, MD, PhD, FASTRO, University of California, San Francisco, San Francisco and receives compensation from Genentech, Merck and BioMimetix.
- Salma Jabbour, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey and receives compensation from IMX Medical, Merck and Syntactx.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website for that 3 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.